Team Identifies Switch For Tumor Suppressor Gene

March 05, 1997

Scientists have identified the protein that determines whether or not a tumor suppressor gene is able to do its job of slowing down or stopping cell growth. The work is a first step toward better control over a gene that plays a role in many cases of human cancer.

The research by a team from the University of Rochester Cancer Center is on the retinoblastoma (RB) gene, one of the first known in a class of genes known as tumor suppressors, whose job it is to rein in cell growth. The work, by Associate Professor John Ludlow, graduate student Deidre Nelson, and post- doctoral researcher Nancy Krucher, appears in the Feb. 14 issue of the Journal of Biological Chemistry.

Cancer is a tale of cells growing out of control, and genes that make proteins that speed up or slow down cell growth are often pivotal in the disease. One such gene codes for the RB protein, which suppresses cell growth. The RB protein is present in all healthy cells, but a mutation can lead to cancer. If this mutation occurs in cells destined to form the eye, a rare but deadly form of childhood eye cancer known as retinoblastoma occurs. More commonly, the gene is missing or mutated in many types of cancer cells such as those found in the lung, breast, and ovary.

"In all cancers, you have cells that proliferate uncontrollably," says Ludlow, the lead investigator and co-author of the book, Tumor Suppressors: Involvement in Human Diseases, Viral Protein Interactions, and Growth Regulation. "We all hope that in the future, we'll be able to put the brakes on runaway cancer cells. One way of doing that may be to control a cell's proliferation through manipulation of the RB protein."

The Rochester group has identified the protein that activates RB to slow down cell proliferation. The protein, known as PP1c, does its work during a very narrow time frame during mitosis, when a cell is dividing.

PP1c turns on RB through a chemical process known as de- phosphorylation, a common process in the body where a protein known as a phosphatase strips phosphate groups off a protein. The stripped-down version of the RB protein suppresses growth by knocking out proteins that a cell needs to proliferate. When the RB protein is decorated with phosphate groups, as it is in many cases of human cancer, RB no longer knocks out these proteins, and cells grow out of control.

"To grow correctly, a cell needs both a gas pedal and a brake pedal," says Ludlow. "The RB protein acts like the brake pedal, reining in growth in a precise and controlled manner. Disable that brake pedal and cells can grow out of control."

The team's research is funded by the National Institutes of Health and by the Sally Edelman and Harry Gardner Cancer Research Foundation of Hilton. Several times a year the group pulls together the Hilton community to raise money for cancer research. Since 1985 the group has contributed nearly one quarter of a million dollars for research at the University of Rochester Cancer Center. The group's next fundraiser is its annual steak roast and raffle Saturday, March 8 at the Hilton Exempt Club from 1 to 6 p.m.
-end-


University of Rochester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.